Assembly Biosciences, Inc. ASMB
We take great care to ensure that the data presented and summarized in this overview for ASSEMBLY BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ASMB
Top Purchases
Top Sells
About ASMB
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Insider Transactions at ASMB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
179,500
+12.39%
|
-
|
|
May 23
2024
|
John G Mc Hutchison |
SELL
Open market or private sale
|
Direct |
2,117
-9.98%
|
$29,638
$14.93 P/Share
|
|
May 23
2024
|
Jeanette M Bjorkquist Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
24
-0.76%
|
$336
$14.93 P/Share
|
|
May 23
2024
|
Jason A Okazaki CEO and President |
SELL
Open market or private sale
|
Direct |
549
-3.3%
|
$7,686
$14.93 P/Share
|
|
May 23
2024
|
Nicole S White Chief Manufacturing Officer |
SELL
Open market or private sale
|
Direct |
172
-1.32%
|
$2,408
$14.93 P/Share
|
|
Apr 30
2024
|
Nicole S White Chief Manufacturing Officer |
SELL
Open market or private sale
|
Direct |
1,255
-8.79%
|
$15,060
$12.71 P/Share
|
|
Apr 30
2024
|
Jason A Okazaki CEO and President |
SELL
Open market or private sale
|
Direct |
1,569
-8.72%
|
$18,828
$12.71 P/Share
|
|
Apr 29
2024
|
Nicole S White Chief Manufacturing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,333
+18.92%
|
-
|
|
Apr 29
2024
|
William E Iv Delaney Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,333
+17.14%
|
-
|
|
Apr 29
2024
|
Jason A Okazaki CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
4,166
+18.8%
|
-
|
|
Apr 01
2024
|
John G Mc Hutchison |
SELL
Open market or private sale
|
Direct |
1,206
-5.38%
|
$15,678
$13.07 P/Share
|
|
Apr 01
2024
|
Jeanette M Bjorkquist Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
114
-3.48%
|
$1,482
$13.07 P/Share
|
|
Apr 01
2024
|
Nicole S White Chief Manufacturing Officer |
SELL
Open market or private sale
|
Direct |
197
-1.77%
|
$2,561
$13.07 P/Share
|
|
Apr 01
2024
|
Jason A Okazaki CEO and President |
SELL
Open market or private sale
|
Direct |
354
-2.5%
|
$4,602
$13.07 P/Share
|
|
Mar 29
2024
|
Jeanette M Bjorkquist Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
850
+20.58%
|
-
|
|
Mar 27
2024
|
Jason A Okazaki CEO and President |
SELL
Open market or private sale
|
Direct |
392
-2.69%
|
$4,704
$12.87 P/Share
|
|
Jan 18
2024
|
Alexander Schornstein > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
345,086
+4.03%
|
$0
$0.8 P/Share
|
|
Jan 17
2024
|
Alexander Schornstein > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
299,994
+3.67%
|
$0
$0.78 P/Share
|
|
Nov 21
2023
|
Alexander Schornstein > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+1.3%
|
$0
$0.67 P/Share
|
|
Nov 20
2023
|
Alexander Schornstein > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+3.86%
|
$0
$0.72 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 134K shares |
|---|---|
| Open market or private purchase | 1.22M shares |
| Open market or private sale | 36.7K shares |
|---|